Gender-Specific Effects in the Treatment of Acute Schizophrenia with Risperidone

T. J. Raedler; A. Schreiner; D. Naber; K. Wiedemann

doi:10.1055/s-2006-948327

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2006; 39(5): 171-174
DOI: 10.1055/s-2006-948327

Original Paper

Gender-Specific Effects in the Treatment of Acute Schizophrenia with Risperidone

T. J. Raedler¹ , A. Schreiner² , D. Naber¹ , K. Wiedemann¹

¹Department of Psychiatry, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
²Department of Medical & Scientific Affairs, Janssen-Cilag, Raiffeisenstr. 8, 41470 Neuss, Germany

Abstract

Introduction: Gender-related effects play a role in antipsychotic treatment. We recently published a study demonstrating the efficacy of the atypical antipsychotic risperidone in the management of acute psychotic decompensations. We have now reanalysed the clinical data to assess the effects of gender on treatment and outcome. Methods: High-dose treatment with risperidone (6-8 mg/d) was administered to 23 male and 25 female acutely psychotic schizophrenic admissions. PANSS- and CGI-ratings were obtained for four weeks. Results: Males and females did not differ significantly in age, duration of treatment, dose of risperidone or clinical ratings. Females were treated with a significantly higher maximum dose of risperidone per kg body-weight. Significantly more females (n=14) than males (n=8) discontinued the use of risperidone. Conclusion: Although the reasons for the lower drop-out rate in males are not clear, gender differences in the clinical presentation may have contributed. High-dose treatment with risperidone may be more beneficial in males for the treatment of acute schizophrenia.

Full Text

References

1 Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G. et al . Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005; 19 395-401
2 Castle DJ, McGrath J, Kulkarni J. Women and schizophrenia. Cambridge, UK; Cambridge University Press 2000
3 Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW. et al . A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13 25-40
4 Csernansky JG, Mahmoud R, Brenner R. The Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002; 346 16-22
5 Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001; 62 153-157
6 Davis JM, Chen N, Glick ID. A Meta-analysis of the Efficacy of Second-Generation Antipsychotics. Arch Gen Psychiatry. 2003; 60 553-564
7 Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Welfare. Washington, D.C. 1976 338: 534-537
8 Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003; 28 ((Suppl 2)) 17-54
9 Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995; 50 222-239
10 Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). Cochrane Database Syst Rev. 2003; 2 CD000440
11 Kaplan HI, Saddock BJ. Kaplan & Saddock's Synopsis of Psychiatry. 8^th ed. Philadelphia; Lippincott Williams & Wilkins 1997
12 Kay SR, Opler LA, Fiszbein A. Positive and negative symptoms in schizophrenia: assessment and research. New York; Bruner Mazel 1991
13 Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. Can J Psychiatry. 2001; 46 534-541
14 Lane HY, Chang YC, Chiu CC, Chen TT, Lee SH, Chang WH. Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. J Clin Psychopharmacol. 2002; 22 353-358
15 Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand. 1999; 99 160-170
16 Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000; 401 3-38
17 Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003; 160 1209-1222
18 Love RC, Nelson MW. Pharmacology and clinical experience with risperidone. Expert Opin Pharmacother. 2000; 1 1441-1453
19 Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol. 2001; 51 317-324
20 Raedler TJ, Schreiner A, Naber D, Wiedemann K. Risperidone in the treatment of acute schizophrenia. J Clin Psychopharmacol. 2004; 24 335-338
21 Salokangas RK. Gender and the use of neuroleptics in schizophrenia. Schizophr Res. 2004; 66 41-49
22 Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003; 42 107-121
23 Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004; 161 1324-1333
24 Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999; 24 339-346

Correspondence

Thomas J. RaedlerM.D.

Department of Psychiatry·University Hospital Hamburg-Eppendorf

Martinistr. 52·20246 Hamburg·Germany

Phone: +49/40/42 80 32 21 0

Fax: +49/40/42 80 38 07 2

Email: traedler@uke.uni-hamburg.de